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Introduction: Rectal cancer with rectovesical fistula is a rare and difficult to treat entity. Here, we describe a case of
rectal cancer with rectovesical fistula successfully managed by multimodality treatment. To the best of our
knowledge, this is the first such case report in the literature.
Case presentation: A 51-year-old Chinese man was diagnosed as having rectal cancer accompanied by
rectovesical fistula. He underwent treatment with neoadjuvant radiochemotherapy combined with total pelvic
excision and adjuvant chemotherapy, as recommended by a multimodality treatment team. Post-operative
pathology confirmed the achievement of pathological complete response.
Conclusions: This case suggests that a proactive multidisciplinary treatment is needed to achieve complete cure of
locally advanced rectal cancer even in the presence of rectovesical fistula.Introduction
Most colorectal cancers in the upper rectum or sigmoid
colon invade the top of the bladder, and they are clinic-
ally treated with a relatively simple en-bloc resection of
the invaded bladder [1]. When the tumor is located in
the anterior wall in the middle of the rectum it is likely
to invade the bladder trigone [1], and when tumor is in
the low rectum it is likely to invade the prostate and
seminal vesicles. Thus, special handling is required for
mid to low rectal cancer, especially in men.Case presentation
A 51-year-old Asian man presented to our facility with
issues of increased stool frequency (six to eight times a
day) accompanied with tenesmus for more than a
month. The stool was shapeless and occasionally mixed
with small amounts of blood. He was admitted due to
worsening of these symptoms and fecaluria accompanied
with fever and severe body weight loss.* Correspondence: zlguj@yahoo.com.cn
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reproduction in any medium, provided the orA protruding peri-rectal lump in the anterior wall with
an uneven surface was found by digital rectal examin-
ation. A colonoscopy examination revealed a mucosal
bulge 4cm from the anal verge with surface erosion and
stenosis. A rectal biopsy confirmed the diagnosis of
moderately differentiated adenocarcinoma. Pelvic com-
puted tomography (CT) showed a rectal cancer that had
invaded the bladder. Cystoscopy revealed a 6×6cm lump
at the six o’clock position of the bladder neck and tri-
gone with ulcerative erosion on the surface, suggesting
an invasion of rectal tumor. Pelvic magnetic resonance
imaging (MRI) showed extensive thickening of the wall
in the upper rectum with a broken outer membrane by
the lesion on the right side that spread to the bladder,
where intestinal contents were observed (Figure 1). Mul-
tiple enlarged lymph nodes were observed next to iliac
vessels inside the mesorectum (Figure 2). The results of
a urine white blood cell test were positive. A chest X-ray
and abdominal ultrasound did not show any distant me-
tastases. Our patient was clinically diagnosed as having
locally advanced rectal cancer, T4bN2M0, stage IIIC,
complicated with rectovesical fistula, incomplete rectal
obstruction, lower gastrointestinal bleeding, and pelvic
local infection.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Magnetic resonance image of rectal cancer prior to
neoadjuvant therapy. Arrow indicates the rectovesical fistula sinus.
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struction, rectal bladder fistula, local hemorrhage and in-
fection, radical resection of the tumor was not suitable. A
multimodality treatment team consisting of surgeons, phy-
sicians, imaging scientists, pathologists and radiologists
suggested conducting a transverse colostomy to bypass
feces first, subsequently performing pre-operative neoad-
juvant therapy when our patient became stable. A week
after transverse colostomy, all his clinical symptomsFigure 2 Magnetic resonance image of rectal cancer prior to
neoadjuvant therapy. Arrow indicates the enlarged lymph nodes
in mesorectum.disappeared and neoadjuvant chemotherapy was admini-
strated using oxaliplatin 80mg once a week (50mg/m2)
and capecitabine 1.5g twice a day (1000mg/m2) for four
weeks, combined with 10MV X-ray intensity modulated
radiation therapy (IMRT) of gross tumor volume (GTV)
50.6Gy/clinical target volume (CTV) 41.8Gy for 22 days.
Two months after neoadjuvant therapy, MRI reassess-
ment showed that the thickness of the upper rectum
wall was reduced with significant tumor reduction. The
lower end of the tumor was located 4cm above the junc-
tion of the levator ani muscle and rectum with local in-
vasion to the muscular layer of the wall. Inside the
mesorectum, the size of the multiple enlarged lymph
nodes next to iliac vessels had also reduced (Figure 3).
The lump size localized on the right mesorectal fascia
was significantly reduced. However, the irregular thick-
ening of the posterior wall of the bladder was still
observed (Figure 4). Positron emission tomography-
computed tomography (PET-CT) confirmed a rectum-
sigmoid junction cancer spreading to the bladder trigone
with metastasis to local lymph nodes of the mesorectum,
retroperitoneal and iliac vascular region. No distant me-
tastasis was detected.
With clinical improvement of the rectovesical fistula
after neoadjuvant therapy, a total pelvic exenteration
(TPE) plus cutaneous ureterostomy was performed for
better treatment of the invaded bladder and involved
pelvic lymph nodes. Pathological analysis of the surgical
specimens (Figures 5, 6, 7) revealed no residual cancer
cells, lymphovascular invasion (LVI) or local lymph
nodes metastasis (out of 22 lymph nodes), suggesting aFigure 3 Magnetic resonance image of rectal cancer after
neoadjuvant radiotherapy. The arrow indicates closure of
rectovesical fistula.
Figure 4 Magnetic resonance image of rectal cancer after
neoadjuvant radiotherapy. The arrow indicates the reduced
tumors. Some enlarged lymph nodes have disappeared.
Figure 6 Specimen of total pelvic exenteration surgery
showing the triangle area of bladder. The arrow indicates the
invasion of rectal cancer through the bladder wall.
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therapy (Figure 8). Five cycles of XELOX regimen (cape-
citabine plus oxaliplatin) were given as adjuvant therapy.
One month after TPE, no abnormal enhancement sites
and enlargement of lymph nodes were found in the pel-
vis by MRI (Figure 9).
Discussion
According to the National Comprehensive Cancer Net-
work (NCCN) guidelines, neoadjuvant therapy should beFigure 5 Specimen of total pelvic exenteration surgery sutured
at the peritoneal reflection. ▹ Indicates the peritoneal reflection,
▸ indicates the mesorectal region, ➩ indicates the rectal region, ➡
indicates the invasion of rectal cancer through the bladder wall.given for the treatment of locally advanced rectal cancer
(LARC) [2]. However, for tumors that invade into the
bladder trigone resulting in rectovesical fistula, the treat-
ment becomes complicated. Therefore, a multidisciplin-
ary clinical team is needed to find comprehensive
solutions [3]. All the symptoms such as fever, blood in
the stool, fecaluria, and incomplete intestinal obstruction
present in our patient resulted from the bladder fistula
caused by local invasion of rectal cancer. After under
going the operation to create a diverting stoma, all his
symptoms disappeared within a week, which helped our
patient undergo further treatment.
The incidence of fecaluria caused by rectovesical fistula
is relatively low in rectal cancer invading the bladder.
Since simple rectal resection would not remove residual
tumor in the bladder, we administered neoadjuvantFigure 7 Profile view of total pelvic exenteration surgery
specimen. ▹ Indicates the necrotic rectal cancer following
chemoradiotherapy, ▸ indicates the closed rectovesical fistula, ➩
indicates the anal region, ➡ indicates the bladder mucosa.
Figure 8 Pathology of resected specimen. Hematoxylin and eosin
stain, ×100.
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50.6Gy of pre-operative radiation [4,5]. The standard pre-
operative treatment for locally invasive rectal cancer in
our hospital included fractional radiation with cumulative
50.4Gy combined with oral administration of capecitabine.
In addition to the standard pre-operative treatment, four
weeks of oxaliplatin was also given in this case to enhance
tumor killing and increase the sensitivity of radiation ther-
apy. This treatment may also contribute to the control of
distant metastasis caused by long-term pre-operative treat-
ment. Reassessment after neoadjuvant therapy showed
tumor shrinkage and absence of distant metastases. A rea-
sonable therapeutic option could be the performance of aFigure 9 Sagittal section of magnetic resonance image after
operation.limited surgical procedure if cystoscopy excludes residual
tumor in the bladder. Then, a strict urologic follow-up
could show eventual vesical relapse and a secondary total
cystectomy could be performed. However, we believe that
pathological analysis is more accurate than cystoscopy for
the diagnosis of residual tumor in the bladder. Consider-
ing the multiple enlarged lymph nodes and the good gen-
eral condition of our patient to tolerate the operation, we
performed TPE. Post-operative adjuvant therapy was car-
ried out based on the opinion that post-operative adjuvant
therapy is necessary even for a PCR of rectal cancer
[2,4,5].
Conclusions
The findings from our patient’s case suggest that a pro-
active multidisciplinary treatment is needed to achieve
complete cure for locally advanced rectal cancer compli-
cated with rectovesical fistula.
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